The world is talking about ending AIDS. AVAC’s advocacy is dedicated to realizing that vision. To get there we must:
At a satellite symposium at the South African AIDS Conference linked to a publication in The Lancet, the ECHO trial of contraceptive use and impact on HIV risk released its results. The topline finding: There was no substantial difference in HIV risk among women using DMPA-IM, the LNG implant or the copper IUD.
This HIV Vaccine Awareness Day, Mitchell Warren talks about this promising and perilous time for vaccines. AVAC has an updated toolkit of resources for translating HIV vaccine research with a renewed sense of urgency. And we invite you to join our vaccine focused webinars.
This HVAD, AVAC has an updated toolkit of resources for translating HIV vaccine research with a renewed sense of urgency, and two dedicated hashtags to rally the call on social media: #HIVvaccineAware and #HVAD2019. We hope you’ll join the conversation!
Gilead’s donation is an acknowledgment that there is a huge issue with PrEP access in America, as in many parts of the world. We welcome this indication that the company grasps the gravity of the situation. However, we urgently need a lower price for all. It’s disappointing that even this small step has taken so long.
AVAC has an extensive online resource library with hundreds of Reports, Publications, Infographics & more. And it includes powerful search features to find exactly what you’re looking for.
AVAC uses education, policy analysis, advocacy, community mobilization and a network of global collaborations to accelerate ethical development and global delivery of biomedical HIV prevention options. Read more
AVAC advocates for a comprehensive response to the epidemic, involving smart use of every proven HIV prevention option available today and sustained research into many new strategies.